A Registry of Participants With Prostate Cancer in Asia

CompletedOBSERVATIONAL
Enrollment

3,644

Participants

Timeline

Start Date

September 9, 2015

Primary Completion Date

September 1, 2020

Study Completion Date

September 1, 2020

Conditions
Prostatic Neoplasms
Interventions
OTHER

No Intervention

This is an observational study. No study medication is provided will be provided as part of participation. Participants disease status, overall survival (OS), PFS, MFS, SRE-free survival, and time to castration (TTC) will be analyzed according to treatments prescribed while enrolled in the registry. All treatment decisions will be made at the discretion of the investigator or treating physician.

Trial Locations (31)

Unknown

Beijing

Guangzhou

Hangzhou

Shanghai

Shenyang

Sichuan

Suzhou

Wuhan

Bangalore

Delhi

Mumbai

New Delhi

Chiba

Hirosaki

Ikoma

Kobe

Koshigaya

Matsuyama

Ōsaka-sayama

Suita

Kuala Lumpur

Kuching

Pulau Pinang

Singapore

Seoul

Kaohsiung City

Tainan City

Taipei

Bangkok

Chiang Mai

Songkhla

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT02546908 - A Registry of Participants With Prostate Cancer in Asia | Biotech Hunter | Biotech Hunter